ARTICLE | Company News

Corcept, National Organization for Rare Disorders (NORD) sales and marketing update

April 16, 2012 7:00 AM UTC

Corcept launched 300 mg oral Korlym mifepristone (formerly Corlux) in the U.S. to treat Cushing's syndrome. The wholesale acquisition price for the once-daily tablet is $186. The progesterone and cortisol receptor antagonist is indicated to control hyperglycemia in adults with endogenous Cushing's syndrome who have Type II diabetes or glucose intolerance. Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol. Korlym has Orphan Drug designation in the U.S. and EU for the indication. ...